Scientific Article
previous document  unige:104582  next document
add to browser collection

Expression of plasminogen activator inhibitors 1 and 2 in lung cancer and their role in tumor progression

Robert, C
Gazzeri, S
Veyrenc, S
Brambilla, C
Brambilla, E
Published in Clinical Cancer Research. 1999, vol. 5, no. 8, p. 2094-2102
Abstract The plasminogen activator cascade initiated by urokinase type plasminogen activator (u-PA) is involved in extracellular matrix degradation during the tumor invasion process. The plasminogen activator inhibitors 1 (PAI-1) and 2 (PAI-2) are two specific inhibitors of u-PA. We hypothesized that the balance between u-PA and its two inhibitors could be disrupted to favor plasminogen activation during lung cancer progression. Using immunohistochemistry, we analyzed the pattern of expression of u-PA, PAI-1, and PAI-2 in non-small cell lung carcinomas (NSCLC) and neuroendocrine (NE) lung tumors. u-PA and PAI-1 were both detected in stromal fibroblasts and in tumor cells. In 84 NSCLCs, their epithelial expression was strongly correlated and linked to the presence of node metastasis (P = 0.008), whereas their coexpression in fibroblasts was associated with larger tumor size (P = 0.04) and advanced stages (P = 0.009). In 72 NE tumors, u-PA and PAI-1 were more frequently expressed in fibroblasts in high-grade NE tumors (SCLC and large cell NE tumors) than in low- and intermediate-grade tumors (typical and atypical carcinoids). Comparison of in situ hybridization and immunohistochemistry in 14 cases showed that PAI-1 was consistently expressed by stromal fibroblasts, although the protein was also localized in tumor cells. In contrast, the expression of PAI-2 was restricted to fibroblasts and correlated with the absence of nodal involvement (P = 0.005). Considering NE tumors, the frequency of PAI-2 expression decreased along the NE spectrum from typical carcinoids to SCLCs. These data suggest that PAI-lacts in synergy with u-PA to favor tumor invasion process and connotes aggressivity, in contrast with PAI-2, which may block u-PA-mediated proteolysis and is inversely correlated with tumor progression.
Keywords Carcinoma, Neuroendocrine/metabolismCarcinoma, Non-Small-Cell Lung/metabolismDisease ProgressionFibroblasts/metabolismHumansImmunohistochemistryIn Situ HybridizationLung Neoplasms/metabolismNeoplasm StagingPlasminogen Activator Inhibitor 1/biosynthesisPlasminogen Activator Inhibitor 2/biosynthesisSerine Proteinase Inhibitors/biosynthesisUrokinase-Type Plasminogen Activator/biosynthesis
PMID: 10473092
Full text
Article (Published version) (767 Kb) - document accessible for UNIGE members only Limited access to UNIGE
(ISO format)
ROBERT, C et al. Expression of plasminogen activator inhibitors 1 and 2 in lung cancer and their role in tumor progression. In: Clinical Cancer Research, 1999, vol. 5, n° 8, p. 2094-2102.

220 hits

0 download


Deposited on : 2018-05-22

Export document
Format :
Citation style :